StreetAlpha.app
Home › Stocks › ALDX

Aldeyra Therapeutics, Inc. (ALDX)

$0.69
▲ +2.18%
LAST CLOSE · NOV 17

Aldeyra Therapeutics is a Concord, Massachusetts biotech developing drug candidates for eye and other immune system diseases. It last closed at $0.69 on Nov 17, up 2.18% on the day.

AI Auto Pilots
Is ALDX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$19.1M
EPS (diluted)
−$0.31
Valuation
Market cap
$41.9M
60.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.0M
At Sep 30
Shareholder equity
$35.2M
Shares outstanding
60.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$57.8M−$57.8MFY2021FY2022: −$62.0M−$62.0MFY2022FY2023: −$37.5M−$37.5MFY2023FY2024: −$55.9M−$55.9MFY2024FY2025: −$33.8M−$33.8MFY2025

From ALDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ALDX in the past 90 days, not enough for a consensus
Average 12-month target
$9.00
▲ 1197.0% upside

Based on 1 analyst who set a price target on ALDX in the past 90 days. The average target is $9.00, with a high of $9.00 and a low of $9.00, compared with the last close of $0.69.

Low $9.00Avg $9.00High $9.00
Blue marker: last close $0.69
Highest target$9.00
Average target$9.00
Lowest target$9.00
Latest rating changes
BTIGReiterated
Sep 29Buy$9
HC Wainwright & Co.Downgrade
Mar 18Hold$2
DateFirmActionRatingPrice target
Sep 29BTIGReiteratedBuy$9
Mar 18HC Wainwright & Co.DowngradeHold$2
Loading…

Technical Analysis

ALDX · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 190% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot at $0.69, and the nearest resistance the swing high (Nov 4) at $0.70.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 10.9%/day
Key levels
$5.9352 week high+759.4%
$2.01200 day average+191.3%
$1.32100 day average+91.3%
$0.9450 day average+36.2%
$0.72Pivot R1+4.3%
$0.70Swing high (Nov 4)+1.4%
$0.69Pivot+0.0%
$0.69Last close
$0.67Pivot S1−2.9%
$0.65Swing low (Oct 16)−5.8%
$0.6420 day average−7.2%
$0.5352 week low−23.2%
Indicators
RSI (14)45.25Middle of its rangeNeutral
MACD-0.07Above its signal lineBullish
Stochastic75.7Middle of its rangeNeutral
ADX (14)30.2Trending up
Williams %R-13.1Oversold below −80, overbought above −20Overbought
CCI (20)121.8Oversold below −100, overbought above 100Overbought
Rate of change+11.8%Change over 10 sessionsBullish
ATR (14)$0.08Typical daily range, 10.9% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALDX

What happened before

See how ALDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALDX in the last 90 days.

Loading…

See today’s whale options flow across the market →

ALDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼35 buying vs 70 selling
  • ▼Held by funds -9.6 pts
  • ▼Funds holding -12
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding96108−11.1%
In funds' top 1001−100.0%
Held by funds51.4%61.0%−9.6 pts
New / increased13 / 2218 / 31−28.6%
Reduced / sold out45 / 2543 / 37−12.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALDX is in one of them and how their past ALDX trades turned out.

ALDX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALDX in an article yet. Here's the latest on the wider market.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company based in Concord, Massachusetts, that develops drug candidates for diseases of the immune system. Its approach uses a family of small molecules called RASP modulators, which act on many proteins at once rather than a single target. Its most advanced candidate, reproxalap, is being studied for dry eye disease and allergic conjunctivitis, and the company is also developing treatments for retinal conditions. It has no approved products yet and plans to sell any future drugs directly or through partners.

Headquarters
Concord, MA